Herpes simplex DNA vaccine - PowderMed

Drug Profile

Herpes simplex DNA vaccine - PowderMed

Alternative Names: Genital herpes vaccine - PowderMed; pPJV7630 HSV2 DNA Vaccine

Latest Information Update: 17 Mar 2008

Price : $50

At a glance

  • Originator PowderMed
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Herpes simplex virus infections

Most Recent Events

  • 17 Mar 2008 HSV2 DNA vaccine is still in phase I trials for herpes simplex virus infections in the US
  • 20 Apr 2006 Chiron was acquired and merged into Novartis
  • 12 Oct 2004 Phase-I clinical trials in Herpes simplex virus infections in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top